DK2075258T3 - Antistof mod RGD i en aminosyresekvens i et ekstracellulært matrixprotein samt fremgangsmåde til dets fremstilling og dets anvendelse - Google Patents

Antistof mod RGD i en aminosyresekvens i et ekstracellulært matrixprotein samt fremgangsmåde til dets fremstilling og dets anvendelse

Info

Publication number
DK2075258T3
DK2075258T3 DK07831013.3T DK07831013T DK2075258T3 DK 2075258 T3 DK2075258 T3 DK 2075258T3 DK 07831013 T DK07831013 T DK 07831013T DK 2075258 T3 DK2075258 T3 DK 2075258T3
Authority
DK
Denmark
Prior art keywords
rgd
antibody
preparation
amino acid
well
Prior art date
Application number
DK07831013.3T
Other languages
English (en)
Inventor
Shigeyuki Kon
Chiemi Kimura
Toshimitsu Uede
Original Assignee
Gene Techno Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Techno Science Co Ltd filed Critical Gene Techno Science Co Ltd
Application granted granted Critical
Publication of DK2075258T3 publication Critical patent/DK2075258T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
DK07831013.3T 2006-10-26 2007-10-25 Antistof mod RGD i en aminosyresekvens i et ekstracellulært matrixprotein samt fremgangsmåde til dets fremstilling og dets anvendelse DK2075258T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006290737 2006-10-26
PCT/JP2007/071279 WO2008050907A1 (fr) 2006-10-26 2007-10-25 Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci

Publications (1)

Publication Number Publication Date
DK2075258T3 true DK2075258T3 (da) 2012-09-17

Family

ID=39324685

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07831013.3T DK2075258T3 (da) 2006-10-26 2007-10-25 Antistof mod RGD i en aminosyresekvens i et ekstracellulært matrixprotein samt fremgangsmåde til dets fremstilling og dets anvendelse

Country Status (9)

Country Link
US (1) US8901280B2 (da)
EP (1) EP2075258B1 (da)
JP (1) JP5399710B2 (da)
KR (1) KR101475960B1 (da)
CN (1) CN101528777B (da)
AU (1) AU2007309979B2 (da)
CA (1) CA2667263C (da)
DK (1) DK2075258T3 (da)
WO (1) WO2008050907A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1968648T3 (da) 2005-12-16 2015-07-27 Amit Shachaf Diagnosesystem til detektering og diagnose af hudcancer
WO2008050907A1 (fr) 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci
KR101746861B1 (ko) * 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도
KR101809761B1 (ko) * 2009-09-24 2017-12-15 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도
AU2021416188A1 (en) 2020-12-31 2023-07-06 Orlucent, Inc. Systems and methods for assessing tissue remodeling

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
CA2370129A1 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
EP1269196B1 (en) 2000-03-23 2007-11-21 Glaxo Group Limited Method of screening for inhibitors of osteopontin
PL366469A1 (en) 2001-04-05 2005-02-07 Immuno-Biological Laboratories Co, Ltd. Anti-osteopontin antibody and use thereof
RU2305111C2 (ru) * 2001-09-25 2007-08-27 Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют Рекомбинантное антитело против остеопонтина и его применение
WO2004103403A1 (ja) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
WO2008050907A1 (fr) 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci
KR101746861B1 (ko) * 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도

Also Published As

Publication number Publication date
KR101475960B1 (ko) 2014-12-23
CN101528777A (zh) 2009-09-09
US20110065899A1 (en) 2011-03-17
CA2667263C (en) 2016-11-08
EP2075258A1 (en) 2009-07-01
EP2075258B1 (en) 2012-06-20
US8901280B2 (en) 2014-12-02
KR20090078356A (ko) 2009-07-17
JPWO2008050907A1 (ja) 2010-02-25
WO2008050907A1 (fr) 2008-05-02
AU2007309979A1 (en) 2008-05-02
EP2075258A4 (en) 2010-08-04
CN101528777B (zh) 2013-03-27
JP5399710B2 (ja) 2014-01-29
AU2007309979B2 (en) 2012-06-28
CA2667263A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
BRPI0919789A2 (pt) metodo para identificar peptídeos e proteínas alergênicas
DK1991584T3 (da) Antistoffer mod human IL-22 og anvendelser deraf
PL1957106T5 (pl) Przeciwciała antagonistyczne skierowane przeciw peptydowi związanemu z genem kalcytoniny i sposoby je wykorzystujące
DK1999259T3 (da) Sekvensspecifik inkorporering af aminosyrer i molekyler
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
KR101369640B1 (ko) 양조 효모의 유용한 단백질 확인 방법
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
PL2942355T3 (pl) Nie-hemolityczne białka fuzyjne llo i ich zastosowanie
DK2007884T3 (da) Cellulasefusionsproteiner og deres anvendelse
DK2154990T3 (da) Funktionelt serumproteinprodukt til anvendelse i spædbørnsernæring samt terapeutiske sammensætninger og fremgangsmåder til deres fremstilling
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
DK2240595T4 (da) Glykosyleret proteinekspression i prokaryoter
IL204037A (en) Saccharide-containing protein conjugates and uses thereof
SI3725330T1 (sl) Stabilne formulacije polipeptidov in njihova uporaba
HUE036759T2 (hu) CRY1Ca és CRY1Fa proteinek kombinált alkalmazása rovarrezisztencia menedzselésére
EP2249794A4 (en) COMPOSITIONS AND METHODS COMPRISING BASIC AMINO ACID PEPTIDES AND PROTEASES
PL2285408T3 (pl) Sekwencje aminokwasowe skierowane przeciwko białkom otoczki wirusa i polipeptydy je zawierające do leczenia chorób wirusowych
BRPI0918027A2 (pt) enzimas de lise de peptidoglicano artificial e proteínas de ligação de peptidoglicano
IL267546B (en) A method for changing the isoelectric point of an antibody through the conversion of an amino acid in cdr
EP2553102A4 (en) HIGH PERFORMANCE EXPRESSION OF RECOMBINANT TOXIN PROTEINS
EP2506857A4 (en) MRNA ADMINISTRATION FOR INCREASING PROTEINS AND ENZYMES IN HUMAN GENETIC DISEASES
DK1973429T3 (da) Proteinhydrolysater og fremgangsmåde til fremstilling
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
EP2052083A4 (en) GENETICALLY PROGRAMMED EXPRESSION OF SELECTIVELY SULFATED PROTEINS IN EU BACTERIA